HIV drug resistance patterns at the epicentre of the HIV-1 epidemic in Kwazulu-Natal, South Africa 2003-2013

Journal of AIDS and Clinical Research

Volumn 5, Issue 5, 2014, Pages

  Kiepiela, Photini ^a   Manasa, Justen ^a   Moosa, Mahomed Yunus ^b   Moodley, Pravi ^c   Gordon, Michelle ^b   Parikh, Urvi M ^d   Sunpath, Henry ^e   de Oliveira, Tulio ^b   Ramjee, Gita ^a  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e MCCORD HOSPITAL   (South Africa)

Author keywords

Acquired; Drug resistance; HIV; Kwazulu Natal; Primary

Indexed keywords

EID: 84903307486     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.1000299     Document Type: Review

References (51)

1. UNAIDS (2012) Global report. UNAIDS report on the global AIDS epIdemic. Geneva, UNAIDS.
2. UNAIDS (2012) UNAIDS World AIDS Day Report.
3. Department of Health RoSA (2012) The 2011 National Antenatal Sentinel HIV & Syphilis Prevalence Survey in South Africa. In: Health Do, editor.
4. Rehle TM, Hallett TB, Shisana O, Pillay-van Wyk V, Zuma K, et al. (2010) A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PLoS One 5: e11094.
5. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML (2013) High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 339: 966-971.
6. Department of Health RoSA (2004) Clinical guideline for the management of HIV and AIDS in adults and adolescents In: Health Do, editor.
7. UNAIDS (2012) HIV treatment now reaching more than 6 million people in sub-Saharan Africa.
8. Johnson FL (2012) Access to Antiretroviral Treatment in South Africa, 2004 -2011. The South African Journal of HIV Medicine 13: 6.
9. Severe P, Leger P, Charles M, Noel F, Bonhomme G, et al. (2005) Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353: 2325-2334.
10. Egger M, Boulle A (2008) Population effect of scaling up ART in resource-poor settings. Lancet 371: 1558-1559.
11. Bor J, Herbst AJ, Newell ML, Bärnighausen T (2013) Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 339: 961-965.
12. Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, et al. (2013) Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med 10: e1001418.
13. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF (2008) Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 13 Suppl 2: 25-36.
14. Parboosing R, Naidoo A, Gordon M, Taylor M, Vella V (2011) Resistance to antiretroviral drugs in newly diagnosed, young treatment-naïve HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa. J Med Virol 83: 1508-1513.
15. Hunt GM, Ledwaba J, Basson AE, Moyes J, Cohen C, et al. (2012) Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009. Clin Infect Dis 54 Suppl 4: S334-338.
16. Gordon M, De Oliveira T, Bishop K, Coovadia HM, Madurai L, et al. (2003) Molecular characteristics of human immunodefciency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies. J Virol 77: 2587-2599.
17. Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira T; Southern Africa Treatment And Resistance Network (SATuRN) (2012) Primary drug resistance in South Africa: data from 10 years of surveys. AIDS Res Hum Retroviruses 28: 558-565.
18. Parikh UM, Kiepiela P, Ganesh S, Gomez K, Horn S, et al. (2013) Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). PLoS One 8: e59787.
19. Shafer RW, Rhee SY, Bennett DE (2008) Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther 13 Suppl 2: 59-68.
20. Pillay V, Ledwaba J, Hunt G, Rakgotho M, Singh B, et al. (2008) Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 13 Suppl 2: 101-107.
21. Iweriebor BC, Mavhandu LG, Masebe T, Rekosh D, Hammarskjold ML, et al. (2012) Molecular epidemiology of HIV in two highly endemic areas of northeastern South Africa. Arch Virol 157: 455-465.
22. Nwobegahay J, Bessong P, Masebe T, Mavhandu L, Manhaeve C, et al. (2011) Prevalence of drug-resistant mutations in newly diagnosed drug-naïve HIV-1-infected individuals in a treatment site in the Waterberg district, Limpopo province. S Afr Med J 101: 335-337.
23. Nwobegahay J, Selabe G, Ndjeka NO, Manhaeve C, Bessong PO (2012) Low prevalence of transmitted genetic drug resistance in a cohort of HIV infected naive patients entering antiretroviral treatment programs at two sites in northern South Africa. J Med Virol 84: 1839-1843.
24. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, et al. (2011) HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 11: 750-759.
25. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, et al. (2011) Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses 27: 5-12.
26. Ndembi N, Hamers RL, Sigaloff KC, Lyagoba F, Magambo B, et al. (2011) Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS 25: 905-910.
27. Aghokeng AF, Kouanfack C, Laurent C, Ebong E, Atem-Tambe A, et al. (2011) Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS 25: 2183-2188.
28. Coffn JM (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267: 483-489.
29. Department of Health RoSA (2010) Clinical guideline for the management of HIV and AIDS in adults and adolescents In: Health Do, editor.
30. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, et al. (2008) Prevalence of HIV-1 drug resistance after failure of a frst highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 46: 1589-1597.
31. Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, et al. (2010) Outcomes after virologic failure of frst-line ART in South Africa. AIDS 24: 1007-1012.
32. Singh A, Sunpath H, Green TN, Padayachi N, Hiramen K, et al. (2011) Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options. J Acquir Immune Defc Syndr 58: 233-240.
33. Sunpath H, Wu B, Gordon M, Hampton J, Johnson B, et al. (2012) High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing frst-line regimen. AIDS 26: 1679-1684.
34. Manasa J, Lessells RJ, Skingsley A, Naidu KK, Newell ML, et al. (2013) High-levels of acquired drug resistance in adult patients failing frst-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa. PLoS One 8: e72152.
35. Parikh UM, Bacheler L, Koontz D, Mellors JW (2006) The K65R mutation in human immunodefciency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 80: 4971-4977.
36. Parikh UM, Barnas DC, Faruki H, Mellors JW (2006) Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis 194: 651-660.
37. Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ, et al. (2013) Comparison of tenofovir, zidovudine, or stavudine as part of frst-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS One 8: e64459.
38. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, et al. (2006) HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20: F9-13.
39. Barth RE, Wensing AM, Tempelman HA, Moraba R, Schuurman R, et al. (2008) Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. AIDS 22: 2210-2212.
40. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, et al. (2009) HIV type-1 clade C resistance genotypes in treatment-naive patients and after frst virological failure in a large community antiretroviral therapy programme. Antivir Ther 14: 523-531.
41. Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, et al. (2009) Viremia, resuppression, and time to resistance in human immunodefciency virus (HIV) subtype C during frst-line antiretroviral therapy in South Africa. Clin Infect Dis 49: 1928-1935.
42. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W (2010) Varied patterns of HIV-1 drug resistance on failing frst-line antiretroviral therapy in South Africa. J Acquir Immune Defc Syndr 53: 480-484.
43. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, et al. (2010) Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 24: 1679-1687.
44. Sigaloff KC, Ramatsebe T, Viana R, de Wit TF, Wallis CL, et al. (2012) Accumulation of HIV drug resistance mutations in patients failing frst-line antiretroviral treatment in South Africa. AIDS Res Hum Retroviruses 28: 171-175.
45. Murphy RA, France H, Sunpath H, Gordon ML, Marconi VC, et al. (2009) Development of dual-class antiretroviral drug resistance in a child coinfected with HIV and tuberculosis: a case report from KwaZulu-Natal, South Africa. J Trop Pediatr 55: 60-62.
46. Green TN, Archary M, Gordon ML, Padayachi N, Lie Y, et al. (2012) Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa. AIDS Res Hum Retroviruses 28: 324-332.
47. Pillay S, Bland R, Lessells R, Manasa J, de Oliveira T, et al. (2013) Drug resistance in children with virological failure on first-line antiretroviral therapy: rural KwaZulu-Natal, South Africa. Paed Infect Dis J. In review.
48. Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, et al. (2005) Thymidine analogue mutation profles: factors associated with acquiring specifc profles and their impact on the virological response to therapy. Antivir Ther 10: 791-802.
49. Rosen S, Long L, Sanne I, Stevens WS, Fox MP (2011) The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc 14: 24.
50. Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, et al. (2012) Patterns of HIV-1 drug resistance after frst-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 54: 1660-1669.
51. Lessells RJ, Avalos A, de Oliveira T (2013) Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in africa: needs, opportunities, and challenges. AIDS Rev 15: 221-229.